GSK terminates agreement for Genaera frog product
13th Nov 2006, 06:59 GMT
GlaxoSmithKline has severed ties with an experimental product -- one derived from the skin of the African clawed frog -- that was once Genaera Corp.'s lead new drug candidate.
GSK terminates agreement for Genaera frog product related news:
- Par Pharmaceutical Announces Agreement With GlaxoSmithKline to Settle Imitrex Injection Patent Litigation — Partnerships/ Joint Ventures News from StratCenter.com
- GSK reaches deal to end patent dispute — Latest news from Triangle Business Journal
- MediPurpose Announces Exclusive Distribution Agreement for Sangofer Blood Separation Product — Government/ Industry Regulation News from StratCenter.com
- EU sets cap on TV ads and product placement — Technology & Media - International Herald Tribune
- XenSource, Inc.: XenSource and Egenera Enter Into OEM Agreement — Market Wire - Computers and Software
- NutriOne Corporation: NutriOne Announces a New Licensing Agreement With Dairy Fresh Farms Inc. for Canada — Market Wire - Energy and Utilities
- Another step backward in playoff chase — Cincinnati Enquirer - Bengals
- GSK Joins With HHS and cdc to Encourage Flu Vaccinations — PR Newswire: All Releases
- $350M would preserve open space — bizjournals.com Business Services:Environmental Services headlines
- Wilkins-Rogers Issues Allergy Alert for Washington Seafood Breader — Kansas City infoZine Headlines
Latest news from bizjournals.com Health Care:Pharmaceuticals headlines:
- United BioSource makes 10th buy, looks for more
- Nonprofits starting to invest in drug companies
- Accentia making changes to its business formula, market focus
- Gladstone and Merck team to bring drugs to market
- Abbott expects to double vascular business sales
- Mayo to shut down drug-testing unit
- MIT, Dana-Farber win major cancer grants
- Service Bancorp chair resigns
- Introgen strikes nanotech deal with M.D. Anderson
- Joslin spins out first-ever company, Veraxa Health Inc.